Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 70

1.

Glucose-lowering therapy and cardiovascular outcomes in patients with type 2 diabetes mellitus and acute coronary syndrome.

Avogaro A, Bonora E, Consoli A, Del Prato S, Genovese S, Giorgino F.

Diab Vasc Dis Res. 2019 Sep;16(5):399-414. doi: 10.1177/1479164119845612. Epub 2019 May 2.

PMID:
31044622
2.

Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study.

Fadini GP, Sciannameo V, Franzetti I, Bottigliengo D, D'Angelo P, Vinci C, Berchialla P, Arena S, Buzzetti R, Avogaro A; DARWIN-T2D network.

Diabetes Obes Metab. 2019 Aug;21(8):1886-1894. doi: 10.1111/dom.13747. Epub 2019 May 8.

PMID:
30985052
3.

Inositol and antioxidant supplementation: Safety and efficacy in pregnancy.

Formoso G, Baldassarre MPA, Ginestra F, Carlucci MA, Bucci I, Consoli A.

Diabetes Metab Res Rev. 2019 Jul;35(5):e3154. doi: 10.1002/dmrr.3154. Epub 2019 Apr 10. Review.

4.

Thromboxane-Dependent Platelet Activation in Obese Subjects with Prediabetes or Early Type 2 Diabetes: Effects of Liraglutide- or Lifestyle Changes-Induced Weight Loss.

Simeone P, Liani R, Tripaldi R, Di Castelnuovo A, Guagnano MT, Tartaro A, Bonadonna RC, Federico V, Cipollone F, Consoli A, Santilli F.

Nutrients. 2018 Dec 2;10(12). pii: E1872. doi: 10.3390/nu10121872.

5.

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.

Hernandez AF, Green JB, Janmohamed S, D'Agostino RB Sr, Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, Thorpe KM, McMurray JJV, Del Prato S; Harmony Outcomes committees and investigators.

Lancet. 2018 Oct 27;392(10157):1519-1529. doi: 10.1016/S0140-6736(18)32261-X. Epub 2018 Oct 2.

PMID:
30291013
6.

Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial.

Bain SC, Mosenzon O, Arechavaleta R, Bogdański P, Comlekci A, Consoli A, Deerochanawong C, Dungan K, Faingold MC, Farkouh ME, Franco DR, Gram J, Guja C, Joshi P, Malek R, Merino-Torres JF, Nauck MA, Pedersen SD, Sheu WH, Silver RJ, Tack CJ, Tandon N, Jeppesen OK, Strange M, Thomsen M, Husain M.

Diabetes Obes Metab. 2019 Mar;21(3):499-508. doi: 10.1111/dom.13553. Epub 2018 Nov 11.

7.

Executive Summary of the 2018 Joint Consensus Document on Cardiovascular Disease Prevention in Italy.

Volpe M, Battistoni A, Gallo G, Rubattu S, Tocci G; Writing Committee; Scientific Societies.

High Blood Press Cardiovasc Prev. 2018 Sep;25(3):327-341. doi: 10.1007/s40292-018-0278-8. Epub 2018 Sep 20. Review.

PMID:
30232768
8.

Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?

Gentilella R, Pechtner V, Corcos A, Consoli A.

Diabetes Metab Res Rev. 2019 Jan;35(1):e3070. doi: 10.1002/dmrr.3070. Epub 2018 Oct 4. Review.

PMID:
30156747
9.

Phenotyping normal kidney function in elderly patients with type 2 diabetes: a cross-sectional multicentre study.

Fadini GP, Solini A, Manca ML, Zatti G, Karamouzis I, Di Benedetto A, Frittitta L, Avogaro A; DARWIN-T2D Network.

Acta Diabetol. 2018 Nov;55(11):1121-1129. doi: 10.1007/s00592-018-1194-z. Epub 2018 Aug 9.

PMID:
30090961
10.

Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study.

Fadini GP, Bottigliengo D, D'Angelo F, Cavalot F, Bossi AC, Zatti G, Baldi I, Avogaro A; DARWIN-T2D Network.

Diabetes Ther. 2018 Aug;9(4):1477-1490. doi: 10.1007/s13300-018-0452-y. Epub 2018 Jun 1.

11.

[Consensus document and recommendations for the prevention of cardiovascular disease in Italy - 2018].

Volpe M, Tocci G, Accettura D, Battistoni A, Bellone S, Bellotti P, Bertolotti M, Borghi C, Casasco M, Consoli A, Coppini R, Corsini A, Costanzo G, Desideri G, Ferri C, Galanti G, Giada F, Icardi G, Lombardi N, Modena MG, Modesti PA, Monti G, Mugelli A, Orsi A, Parati G, Pedretti RF, Perseghin G, Pirro M, Ricotti R, Rizzoni D, Rotella C, Rubattu S, Salvetti G, Sarto P, Tassinari F, Trimarco B, de Kreutzenberg SV, Volpe R.

G Ital Cardiol (Rome). 2018 Feb;19(2 Suppl 1):1S-95S. doi: 10.1714/2874.28988. Italian.

PMID:
29531376
12.

Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study.

Fadini GP, Zatti G, Baldi I, Bottigliengo D, Consoli A, Giaccari A, Sesti G, Avogaro A; DARWIN-T2D network.

Diabetes Obes Metab. 2018 Jul;20(7):1781-1786. doi: 10.1111/dom.13280. Epub 2018 Mar 30.

13.

Cardiovascular biomarkers in clinical studies of type 2 diabetes.

Baldassarre MPA, Andersen A, Consoli A, Knop FK, Vilsbøll T.

Diabetes Obes Metab. 2018 Jun;20(6):1350-1360. doi: 10.1111/dom.13247. Epub 2018 Mar 5. Review.

PMID:
29419909
14.

A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment.

Consoli A, Formoso G, Baldassarre MPA, Febo F.

Expert Opin Drug Saf. 2018 Mar;17(3):293-302. doi: 10.1080/14740338.2018.1428305. Epub 2018 Jan 19. Review.

PMID:
29334278
15.

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.

Dandona P, Mathieu C, Phillip M, Hansen L, Griffen SC, Tschöpe D, Thorén F, Xu J, Langkilde AM; DEPICT-1 Investigators.

Lancet Diabetes Endocrinol. 2017 Nov;5(11):864-876. doi: 10.1016/S2213-8587(17)30308-X. Epub 2017 Sep 14. Erratum in: Lancet Diabetes Endocrinol. 2017 Dec;5(12 ):e8.

PMID:
28919061
16.

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial.

Vaccaro O, Masulli M, Nicolucci A, Bonora E, Del Prato S, Maggioni AP, Rivellese AA, Squatrito S, Giorda CB, Sesti G, Mocarelli P, Lucisano G, Sacco M, Signorini S, Cappellini F, Perriello G, Babini AC, Lapolla A, Gregori G, Giordano C, Corsi L, Buzzetti R, Clemente G, Di Cianni G, Iannarelli R, Cordera R, La Macchia O, Zamboni C, Scaranna C, Boemi M, Iovine C, Lauro D, Leotta S, Dall'Aglio E, Cannarsa E, Tonutti L, Pugliese G, Bossi AC, Anichini R, Dotta F, Di Benedetto A, Citro G, Antenucci D, Ricci L, Giorgino F, Santini C, Gnasso A, De Cosmo S, Zavaroni D, Vedovato M, Consoli A, Calabrese M, di Bartolo P, Fornengo P, Riccardi G; Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study group; Italian Diabetes Society.

Lancet Diabetes Endocrinol. 2017 Nov;5(11):887-897. doi: 10.1016/S2213-8587(17)30317-0. Epub 2017 Sep 13. Erratum in: Lancet Diabetes Endocrinol. 2017 Nov;5(11):e7.

PMID:
28917544
17.

Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes.

Santilli F, Simeone PG, Guagnano MT, Leo M, Maccarone MT, Di Castelnuovo A, Sborgia C, Bonadonna RC, Angelucci E, Federico V, Cianfarani S, Manzoli L, Davì G, Tartaro A, Consoli A.

Diabetes Care. 2017 Nov;40(11):1556-1564. doi: 10.2337/dc17-0589. Epub 2017 Sep 14.

PMID:
28912305
18.

Liraglutide and Renal Outcomes in Type 2 Diabetes.

Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators.

N Engl J Med. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011.

19.

Liraglutide mitigates TNF-α induced pro-atherogenic changes and microvesicle release in HUVEC from diabetic women.

Di Tomo P, Lanuti P, Di Pietro N, Baldassarre MPA, Marchisio M, Pandolfi A, Consoli A, Formoso G.

Diabetes Metab Res Rev. 2017 Nov;33(8). doi: 10.1002/dmrr.2925. Epub 2017 Sep 6.

PMID:
28753251
20.

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.

Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, Buse JB; DEVOTE Study Group.

N Engl J Med. 2017 Aug 24;377(8):723-732. doi: 10.1056/NEJMoa1615692. Epub 2017 Jun 12.

Supplemental Content

Loading ...
Support Center